The dopamine metabolite aminochrome inhibits mitochondrial complex i and modifies the expression of iron transporters DMT1 and FPN1

BioMetals

Volumn 25, Issue 4, 2012, Pages 795-803

  Aguirre, Pabla ^a   Urrutia, Pamela ^a   Tapia, Victoria ^a   Villa, Monica ^b   Paris, Irmgad ^b   Segura Aguilar, Juan ^b   Núñez, Marco T ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Complex I activity; DMT1 isoforms; Dopamine metabolism; Ferroportin 1; Iron accumulation

Indexed keywords

AMINOCHROME; FERROPORTIN 1; IRON; MEMBRANE PROTEIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PROTEIN FPN1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TOXIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEREGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNODETECTION; NEUROBLASTOMA CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DOPAMINE; ELECTRON TRANSPORT COMPLEX I; HUMANS; INDOLEQUINONES; MITOCHONDRIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84864914669     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-012-9525-y     Document Type: Article

References (47)

1. Aguirre P, Mena N, Tapia V, Arredondo M, Núñez MT (2005) Iron homeostasis in neuronal cells: a role for IREG1. BMC Neurosci 6:3
2. Aguirre P, Valdes P, Aracena-Parks P, Tapia V, Núñez MT (2007) Upregulation of gamma-glutamate-cysteine ligase as part of the long-term adaptation process to iron accumulation in neuronal SH-SY5Y cells. Am J Physiol Cell Physiol 292(6):C2197-C2203
3. Altamura S, Muckenthaler MU (2009) Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 16(4):879-895
4. Aras MA, Hartnett KA, Aizenman E (2008) Assessment of cell viability in primary neuronal cultures. Curr Protoc Neurosci Chapter 7:Unit 7 18
5. Arredondo M, Orellana A, Garate MA, Núñez MT (1997) Intracellular iron regulates iron absorption and IRP activity in intestinal epithelial (Caco-2) cells. Am J Physiol 273(2 Pt 1):G275-G280
6. Arriagada C, Paris I, De las Sanchez Matas MJ, Martinez- Alvarado P, Cardenas S, Castaneda P, Graumann R, Perez- Pastene C, Olea-Azar C, Couve E, Herrero MT, Caviedes P, Segura-Aguilar J (2004) On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol Dis 16(2):468-477
7. Bautista J, Corpas R, Ramos R, Cremades O, Gutierrez JF, Alegre S (2000) Brain mitochondrial complex I inactivation by oxidative modification. Biochem Biophys Res Commun 275(3):890-894
8. Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 73(3):1127-1137
9. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's diseaserelated pathology. Cell Tissue Res 318(1):121-134
10. Broom L, Marinova-Mutafchieva L, Sadeghian M, Davis JB, Medhurst AD, Dexter DT (2011) Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease. Free Radic Biol Med 50(5):633-640
11. Bulteau AL, Ikeda-Saito M, Szweda LI (2003) Redox-dependent modulation of aconitase activity in intact mitochondria. Biochemistry 42(50):14846-14855
12. Castellani RJ, Perry G, Siedlak SL, Nunomura A, Shimohama S, Zhang J, Montine T, Sayre LM, Smith MA (2002) Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 319(1):25-28
13. Chinopoulos C, Adam-Vizi V (2001) Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson's disease. J Neurochem 76(1):302-306
14. Clementi E, Brown GC, Feelisch M, Moncada S (1998) Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA 95(13):7631-7636
15. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, Gallego C, Comella JX (2000) Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 75(3):991-1003
16. Gluck MR, Zeevalk GD (2004) Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamineassociated diseases. J Neurochem 91(4):788-795
17. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45(6):1138-1143
18. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50(5):1346-1350
19. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, Hill R, Shults CW (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 37(6):714-722
20. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 56(2):446-451
21. Humphries KM, Yoo Y, Szweda LI (1998) Inhibition of NADHlinked mitochondrial respiration by 4-hydroxy-2-nonenal. Biochemistry 37(2):552-557
22. Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P (2005) A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur J Neurosci 21(4):841-854
23. Jana S, Maiti AK, Bagh MB, Banerjee K, Das A, Roy A, Chakrabarti S (2007) Dopamine but not 3, 4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease. Brain Res 1139:195-200
24. Kell DB (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84(11):825-889
25. Khan FH, Sen T, Maiti AK, Jana S, Chatterjee U, Chakrabarti S (2005) Inhibition of rat brain mitochondrial electron transport chain activity by dopamine oxidation products during extended in vitro incubation: implications for Parkinson's disease. Biochim Biophys Acta 1741(1-2):65-74
26. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH (1992) Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol 32(6):782-788
27. Langston JW (1985) MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci 36(3): 201-206
28. Lv Z, Jiang H, Xu H, Song N, Xie J (2011) Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm 118(3):361-369
29. Mena NP, Esparza A, Tapia V, Valdes P, Núñez MT (2008) Hepcidin inhibits apical iron uptake in intestinal cells. Am J Physiol Gastrointest Liver Physiol 294(1):G192-G198
30. Mena NP, Bulteau AL, Salazar J, Hirsch EC, Núñez MT (2011) Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity. Biochem Biophys Res Commun 409(2):241-246
31. Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of alpha-synuclein by advanced glycation endproducts: an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20(3-4):253-257
32. Núñez MT, Tapia V, Rojas A, Aguirre P, Gomez F, Nualart F (2010) Iron supply determines apical/basolateral membrane distribution of intestinal iron transporters DMT1 and ferroportin 1. Am J Physiol Cell Physiol 298(3):C477-C485
33. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH (2010) Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5(1):e8762
34. Paris I, Perez-Pastene C, Cardenas S, Iturriaga-Vasquez P, Munoz P, Couve E, Caviedes P, Segura-Aguilar J (2010) Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigraderived cell line. Neurotoxic Res 18(1):82-92
35. Remor AP, de Matos FJ, Ghisoni K, da Silva TL, Eidt G, Burigo M, de Bem AF, Silveira PC, de Leon A, Sanchez MC, Hohl A, Glaser V, Goncalves CA, Quincozes-Santos A, Borba Rosa R, Latini A (2011) Differential effects of insulin on peripheral diabetes-related changes in mitochondrial bioenergetics: involvement of advanced glycosylated end products. Biochim Biophys Acta 1812(11):1460-1471
36. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick LM, Núñez MT, Garrick MD, Raisman-Vozari R, Hirsch EC (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 105(47): 18578-18583
37. Schapira AH (2010) Complex I: inhibitors, inhibition and neurodegeneration. Exp Neurol 224(2):331-335
38. Schapira AH, Jenner P (2011) Etiology and pathogenesis of Parkinson's disease. Mov Disord 26(6):1049-1055
39. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54(3):823-827
40. Segura-Aguilar J, Metodiewa D, Welch CJ (1998) Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 1381(1):1-6
41. Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118(6):939-957
42. Sims NR, Anderson MF, Hobbs LM, Kong JY, Phillips S, Powell JA, Zaidan E (2000) Impairment of brain mitochondrial function by hydrogen peroxide. Brain Res Mol Brain Res 77(2):176-184
43. Song N, Wang J, Jiang H, Xie J (2010) Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. Free Radic Biol Med 48(2):332-341
44. Vymazal J, Righini A, Brooks RA, Canesi M, Mariani C, Leonardi M, Pezzoli G (1999) T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211(2):489-495
45. Youdim MB, Ben-Shachar D, Riederer P (1989) Is Parkinson'sdisease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl 126:47-54
46. Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies KJ (1990) The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem 265(27):16330-16336
47. Zoccarato F, Toscano P, Alexandre A (2005) Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease. J Biol Chem 280(16):15587-15594